Skip to main content
    C

    Collegium Pharmaceutical Inc (COLL)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $25.43
    +0.11 (+0.43%)

    Market Cap: $786.83M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Collegium Pharmaceutical Inc (COLL) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Collegium Pharmaceutical (COLL) trades at 3.7x trailing earnings and 1.0x sales. Its P/E of 3.7x is below its 5-year median of 6.2x. Its forward P/E is 3.7x. The median P/E across 11 similar companies is 10.7x.

    Current Multiples

    Its enterprise value is 4.9x its EBITDA. Its free cash flow yield is 41.7%.

    MultipleValue
    P/E (trailing)3.7x
    Forward P/E3.7x
    Price to sales1.0x
    Price to book2.7x
    EV/EBITDA4.9x
    Price to FCF2.4x
    EV/FCF5.2x
    PEG0.7
    FCF yield41.7%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 50.0% below 2.0x and its P/B is 35.7% below 4.2x.

    MultipleCurrent5-year median10-year median
    P/E3.7x6.2xN/A
    P/S1.0x1.7x2.0x
    P/B2.7x4.1x4.2x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 7 of the 10 year ends shown that have a P/E, its P/E ranged from 4.4x in 2024 to 82.3x in 2019.

    Year endPriceP/EP/SP/B
    2025$46.306.6x2.0x6.1x
    2024$28.654.4x1.6x5.0x
    2023$30.785.6x2.0x6.6x
    2022$23.207.7x1.7x4.0x
    2021$18.689.2x2.4x3.1x
    2020$20.039.1x2.2x3.8x
    2019$20.5882.3x2.3x7.9x
    2018$17.17N/A2.0x6.3x
    2017$18.46N/A20.0x5.8x
    2016$15.57N/A237.8x3.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About COLL

    What is COLL's forward P/E ratio?

    Collegium Pharmaceutical has a forward P/E ratio of 3.7x.

    Is COLL stock overvalued?

    GNG's valuation label for COLL is Undervalued. Its P/E of 3.7x compares with a median of 10.7x across 11 similar companies.

    What is COLL's price to sales ratio?

    Collegium Pharmaceutical has a price to sales ratio of 1.0x.

    What is Collegium Pharmaceutical's average P/E ratio over 5 years?

    Collegium Pharmaceutical's median P/E over the last 5 years is 6.2x, from 60 month-end values through Oct 2026.

    What is COLL's PEG ratio?

    Collegium Pharmaceutical has a PEG ratio of 0.7.